Amgen Inc. (BMV:AMGN)

Mexico flag Mexico · Delayed Price · Currency is MXN
6,540.15
+190.15 (2.99%)
At close: Feb 6, 2026
Market Cap3.48T +16.2%
Revenue (ttm)661.64B +10.0%
Net Income138.82B +88.5%
EPS256.19 +88.2%
Shares Outn/a
PE Ratio25.05
Forward PE16.73
Dividend183.45 (2.81%)
Ex-Dividend DateNov 21, 2025
Volume59
Average Volume796
Open6,400.00
Previous Close6,350.00
Day's Range6,400.00 - 6,540.15
52-Week Range5,023.00 - 6,680.00
Beta0.45
RSI62.45
Earnings DateFeb 3, 2026

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]

Sector Healthcare
Founded 1980
Employees 28,000
Stock Exchange Mexican Stock Exchange
Ticker Symbol AMGN
Full Company Profile

Financial Performance

In 2025, Amgen's revenue was $36.75 billion, an increase of 9.95% compared to the previous year's $33.42 billion. Earnings were $7.71 billion, an increase of 88.53%.

Financial numbers in USD Financial Statements